Dr. Pal on the Mutational Burden in Bladder Cancer

Sumanta Kumar Pal, MD
Published: Wednesday, Dec 27, 2017



Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

There are multiple data sets that suggest that PD-L1 status has varying potential in terms of predictive capabilities across the spectrum of agents that are approved for patients with metastatic urothelial cancer, says Pal.

Tumor mutational burden may be relevant in selecting ideal pairings of drugs, explains Pal.

SELECTED
LANGUAGE


Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

There are multiple data sets that suggest that PD-L1 status has varying potential in terms of predictive capabilities across the spectrum of agents that are approved for patients with metastatic urothelial cancer, says Pal.

Tumor mutational burden may be relevant in selecting ideal pairings of drugs, explains Pal.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x